Lexeo Reports Positive Interim Phase 1/2 Clinical Data With LX2006 - Quick Facts
(RTTNews) - Lexeo Therapeutics (LXEO) reported positive interim data of LX2006 for the treatment of Friedreich ataxia cardiomyopathy. The company said the interim data demonstrated clinically meaningful improvements across multiple cardiac biomarkers of hypertrophy, a hallmark of FA cardiomyopathy.
Eric Adler, Chief Medical Officer and Head of Research at Lexeo Therapeutics, said: "Based on the favorable safety profile and clinical benefits observed to date, we are excited to explore expedited clinical development of LX2006, including potential for accelerated approval of this possibly life-saving treatment."
For More Such Health News, visit rttnews.com.
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.